[1] Hunger SP, Lu X, Devidas M, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005:a report from the children's oncology group[J]. J Clin Oncol, 2012, 30(14):1663-1669.
[2] Zhai XW, Cheng FW, Lee V, et al. Improved survival outcome of childhood acute myeloid leukemia with intensified chemotherapy in Chinese children[J]. Pediatr Hematol Oncol, 2011, 28(4):269- 278.
[3] 陈波, 宪莹, 苏庸春, 等. CCLG-ALL08 方案治疗儿童急性淋 巴细胞白血病毒副作用的临床研究[J]. 中国当代儿科杂志, 2013, 15(9):737-742.
[4] Eden T. Aetiology of childhood leukaemia[J]. Cancer Treat Rev, 2010, 36(4):286-297.
[5] Pui CH, Carroll WL, Meshinchi S, et al. Biology, risk stratification, and therapy of pediatric acute leukemias:an update[J]. J Clin Oncol, 2011, 29(5):551-565.
[6] 竺晓凡. 如何提高儿童急性髓系白血病的疗效[J]. 中国当代 儿科杂志, 2014, 16(2):108-110.
[7] Offenmuller S, Ravindranath Y, Goyette G, et al. Focused screening of a panel of cancer-related genetic polymorphisms reveals new susceptibility loci for pediatric acute lymphoblastic leukemia[J]. Pediatr Blood Cancer, 2014, 61(8):1411-1415.
[8] Gutierrez-Camino A, Lopez-Lopez E, Martin-Guerrero I, et al. Intron 3 of the ARID5B gene:a hot spot for acute lymphoblastic leukemia susceptibility[J]. J Cancer Res Clin Oncol, 2013, 139(11):1879-1886.
[9] Seavey MM, Dobrzanski P. The many faces of Janus kinase[J]. Biochem Pharmacol, 2012, 83(9):1136-1145.
[10] Lai SY, Johnson FM. Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies:Implications for future therapeutic approaches[J]. Drug Resistance Updates, 2010, 13(3):67-78.
[11] Ungureanu D, Wu J, Pekkala T, et al. The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling[J]. Nature Struct Mol Biol, 2011, 18(9):971-976.
[12] Lee HJ, Daver N, Kantarjian HM, et al. The role of JAK pathway dysregulation in the pathogenesis and treatment of acute myeloid leukemia[J]. Clin Cancer Res, 2013,9(2):27-335.
[13] Silvennoinen O, Ungureanu D, Niranjan Y, et al. New insights into the structure and function of the pseudokinase domain in JAK2[J]. Bioch Society Transact, 2013, 41(4):1002-1007.
[14] Brooks AJ, Dai W, O'Mara ML, et al. Mechanism of activation of protein kinase JAK2 by the growth hormone receptor[J]. Science, 2014, 344(6185):1249783.
[15] Agrawal S, Gollapudi S, Su H, et al. Leptin activates human B cells to secrete TNF-α, IL-6, and IL-10 via JAK2/STAT3 and p38MAPK/ERK1/2 signaling pathway[J]. J Clin Immunol, 2011, 31(3):472-478.
[16] Zhang F, Li C, Halfter H, et al. Delineating an oncostatin M-activated STAT3 signaling pathway that coordinates the expression of genes involved in cell cycle regulation and extracellular matrix deposition of MCF-7 cells[J]. Oncogene, 2003, 22(6):894-905.
[17] Dawson MA, Bannister AJ, Göttgens B, et al. JAK2 phosphorylates histone H3Y41 and excludes HP1α from chromatin[J]. Nature, 2009, 461(7265):819-822.
[18] Zamora L, Xandri M, Garcia O, et al. Association of JAK2 mutation status and cytogenetic abnormalities at diagnosis in myeloproliferative neoplasms and myelodysplastic/ myeloproliferative neoplasms[J]. Am J Clin Pathol, 2012, 137(4):677-678.
[19] Salmoiraghi S, Montalvo ML, D'Agostini E, et al. Mutations and chromosomal rearrangements of JAK2:not only a myeloid issue[J]. Expert Rev Hematol, 2013, 6(4):429-439.
[20] Etheridge SL, Cosgrove ME, Sangkhae V, et al. A novel activating, germline JAK2 mutation, JAK2R564Q, causes familial essential thrombocytosis[J]. Blood, 2014, 123(7):1059- 1068.
[21] Rampal R, Mascarenhas J. Pathogenesis and management of acute myeloid leukemia that has evolved from a myeloproliferative neoplasm[J]. Current Opin Hematol, 2014, 21(2):65-71.
[22] Cancer Genome Atlas Research Network. Genomic and epigenomic Landscapes of adult de novo acute myeloid leukemia[J]. NEJM, 2013, 368(22):2059-2074.
[23] Zhang SJ, Rampal R, Manshouri T, et al. Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome[J]. Blood, 2012, 119(19):4480-4485.
[24] Wang M, He N, Tian T, et al. Mutation analysis of JAK2V617F, FLT3-ITD, NPM1, and DNMT3A in Chinese patients with myeloproliferative neoplasms[J]. Biomed Res Int, 2014, 2014:485645.
[25] Nielsen C, Bojesen SE, Nordestgaard BG, et al. JAK2V617F somatic mutation in the general population:myeloproliferative neoplasm development and progression rate[J]. Haematologica, 2014, 99(9):1448-1455.
[26] Abdel-Wahab O, Manshouri T, Patel J, et al. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias[J]. Cancer Res, 2010, 70(2):447-452.
[27] Lee JW, Kim YG, Soung YH, et al. The JAK2 V617F mutation in de novo acute myelogenous leukemias[J]. Oncogene, 2006, 25(9):1434-1436.
[28] Rampal R, Ahn J, Abdel-Wahab O, et al. Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms[J]. Proc Natl Acad Sci U S A, 2014, 111(50):E5401-E5410.
[29] Beer PA, Delhommeau F, LeCouedic JP, et al. Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm[J]. Blood, 2010, 115(14):2891- 2900.
[30] Swaminathan S, Madkaikar M, Ghosh K, et al. Novel immunophenotypic and morphologic presentation in acute myeloid leukemia (AML) with[J]. Europ J Haematol, 2010, 84(2):180-182.
[31] Ikezoe T, Kojima S, Furihata M, et al. Expression of p-JAK2 predicts clinical outcome and is a potential molecular target of acute myelogenous leukemia[J]. Int J Cancer, 2011, 129(10):2512-2521.
[32] Kratz CP, Böll S, Kontny U, et al. Mutational screen reveals a novel JAK2 mutation, L611S, in a child with acute lymphoblastic leukemia[J]. Leukemia, 2005, 20(2):381-383.
[33] Funakoshi-Tago M, Tago K, Sumi K, et al. The Acute Lymphoblastic Leukemia-associated JAK2 L611S Mutant Induces Tumorigenesis in Nude Mice[J]. J Biol Chem, 2009, 284(19):12680-12690.
[34] Li F, Guo HY, Wang M, et al. The effects of R683S (G) genetic mutations on the JAK2 activity, structure and stability[J]. Int J Biol Macromol, 2013, 60:186-195.
[35] Wu QY, Guo HY, Li F, et al. Disruption of E627 and R683 interaction is responsible for B-cell acute lymphoblastic leukemia caused by JAK2 R683G(S) mutations[J]. Leuk Lymphoma, 2013, 54(12):2693-2700.
[36] Mullighan CG, Zhang J, Harvey RC, et al. JAK mutations in high-risk childhood acute lymphoblastic leukemia[J]. Proc Natl Acad Sci U S A, 2009, 106(23):9414-9418.
[37] Chen IM, Harvey RC, Mullighan CG, et al. Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia:a Children's Oncology Group study[J]. Blood, 2012, 119(15):3512-3522.
[38] Buitenkamp TD, Pieters R, Gallimore NE, et al. Outcome in children with Down's syndrome and acute lymphoblastic leukemia:role of IKZF1 deletions and CRLF2 aberrations[J]. Leukemia, 2012, 26(10):2204-2211.
[39] Haan C, Behrmann I, Haan S. Perspectives for the use of structural information and chemical genetics to develop inhibitors of Janus kinases[J]. J Cell Mol Med, 2010, 14(3):504-527.
[40] Zhong Y, Wu J, Ma R, et al. Association of Janus kinase 2 (JAK2) polymorphisms with acute leukemia susceptibility[J]. Int J Lab Hematol, 2012, 34(3):248-253.
[41] Nahajevszky S, Andrikovics H, Batai A, et al. The prognostic impact of germline 46/1 haplotype of Janus kinase 2 in cytogenetically normal acute myeloid leukemia[J]. Haematologica, 2011, 96(11):1613-1618.
[42] Verstovsek S, Silver RT, Talpaz M, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis[J]. NEJM, 2012, 366(9):799-807.
[43] Levis M, Ravandi F, Wang ES, et al. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse[J]. Blood, 2011, 117(12):3294-3301.
[44] Pardanani A, Laborde RR, Lasho TL, et al. Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis[J]. Leukemia, 2013, 27(6):1322-1327.
[45] Pardanani A, Gotlib JR, Jamieson C, et al. Safety and efficacy of TG101348, a sSelective JAK2 inhibitor, inmyelofibrosis[J]. J Clin Oncol, 2011, 29(7):789-796.
[46] Weisberg E, Liu Q, Nelson E, et al. Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3- positive AML:synergism between FLT3 inhibitors, dasatinib/ multi-targeted inhibitors and JAK inhibitors[J]. Leukemia, 2012, 26(10):2233-2244.
[47] Hart S, Goh KC, Novotny-Diermayr V, et al. SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies[J]. Leukemia, 2011, 25(11):1751-1759.
[48] Novotny-Diermayr V, Hart S, Goh KC, et al. The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML[J]. Blood Cancer J, 2012, 2(5):e69.
[49] Verstovsek S, Silver RT, Talpaz M, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis[J]. NEJM, 2012, 366(9):799-807.
[50] Barosi G, Zhang MJ, Peter GR. Does ruxolitinib improve survival of persons with MPN-associated myelofibrosis? Should it?[J]. Leukemia, 2014, 28(11):2267-2270.
[51] Kesarwani M, Huber E, Azam M. Overcoming AC220 resistance of FLT3-ITD by SAR302503[J]. Blood Cancer J, 2013, 3:e138.
[52] Verstovsek S, Tam CS, Wadleigh M, et al. Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor[J]. Leukemia Res, 2014, 38(3):316-322.
[53] Shide K, Kameda T, Markovtsov V, et al. R723, a selective JAK2 inhibitor, effectively treats JAK2V617F-induced murine myeloproliferative neoplasm[J]. Blood, 2011, 117(25):6866- 6875.
[54] Cook AM, Li L, Ho Y, et al. Role of altered growth factor receptor-mediated JAK2 signaling in growth and maintenance of human acute myeloid leukemia stem cells[J]. Blood, 2014, 123(18):2826-2837.
[55] Abdel-Aziz MM. Clinical significance of serum p53 and epidermal growth factor receptor in patients with acute leukemia[J]. Asian Pac J Cancer Prev, 2013, 14(7):4295-4299.
[56] DeAngelo DJ, Neuberg D, Amrein PC, et al. A phase II study of the EGFR inhibitor gefitinib in patients with acute myeloid leukemia[J]. Leuk Res, 2014, 38(4):430-434.
[57] Lainey E, Wolfromm A, Sukkurwala AQ, et al. EGFR inhibitors exacerbate differentiation and cell cycle arrest induced by retinoic acid and vitamin D[J]. Cell Cycle, 2014, 12(18):2978- 2991.